Pfizer Ltd

Information

Name

Pfizer Ltd

Type

Company

Roles

Supplier

Company Size

Large

Company Number

Incorporation Date

Website

https://etendersni.gov.uk/epps

Address

Tadworth

United Kingdom

Suppliers

Unlock the full supplier list, free!

Sign up to unlock the full list of suppliers associated with Pfizer Ltd
Sign up free

Contracts awarded to Pfizer Ltd

The contracts that Pfizer Ltd have been awarded to supply. Click on the contract to view more detailed information and view the full details about the contract won.

Award

Published 3 months ago

Pneumococcal vaccine for adults and at risk (2025)

Provision of pneumococcal vaccine for adults and at risk groups (2025)

£1
Award

Published 3 months ago

NHS National Generic Pharmaceuticals Wave 15a

NHS National Generic Pharmaceuticals - Wave 15a. Offer reference number: CM/PHG/23/5697. Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/23/5697/01 – Orals (plus non-parenteral) Products: All Regions (CESW/LSNE/NWLN): 01/02/2025 to 31/05/2027 (28 Months) CM/PHG/23/5697/02 – Hospital Only Products: DNW & DLN: 01/02/2025 to 31/01/2027 (24 months) CM/PHG/23/5697/03 – Hospital Only Products (Housekeeping): DLS & DNE: 01/02/2025 to 31/05/2026 (16 months) DCE & DSW: 01/02/2025 to 30/09/2025 (8 months)

£170
Award

Published 7 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

£380,950,720 Bids close: 1 year ago
Award

Published 7 months ago

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.

£39
Award

Published 8 months ago

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

Generic, Branded Generic & Proprietary Medicinal Products - Group 14 (5190931)

£10,725,841
Award

Published 8 months ago

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024 Offer reference number: CM/PHS/22/5661 Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months. Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England

£765,000,000 Bids close: 1 year ago

Contacts

+44 7471112086

[email protected]

Statistics (1 Year)

Contracts Won

Total Won

£1,562,434,322

Average Win

£156,243,432

Pfizer Ltd

Information

Name

Type

Roles

Company Size

Company Number

Incorporation Date

Website

Address

Suppliers

Contracts awarded to Pfizer Ltd

Pneumococcal vaccine for adults and at risk (2025)

NHS National Generic Pharmaceuticals Wave 15a

NHS Branded Medicines Tranche Framework for London and South of England

NHS Branded Medicines Tranche Framework for London and South of England

Generic, Branded Generic & Proprietary Medicinal Products - Group 14

NHS Framework - Blood Disorders including Haemophilia A and B - July 2024

Contacts

Statistics (1 Year)

Contracts Won

Total Won

Average Win